View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
July 21, 2021

Coronavirus company news summary – Enzo Biochem gets EUA for rapid extraction on Covid-19 test system – Quest Diagnostics and CLX Health partner on live event testing

By Chloe Kent

Enzo Biochem has obtained US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for a rapid extraction method on its AMPIPROBE test system to identify SARS-CoV-2, including genetic variants. The new extraction method will allow laboratories to cut the time by one hour or about 25%, in turn facilitating more tests on one instrument.

Chembio Diagnostics has secured a $28.3m purchase order from Bio-Manguinhos for its DPP SARS-CoV-2 Antigen test to be delivered this year for Covid-19 testing in Brazil. The test, which can potentially identify the SARS-CoV-2 antigen from a nasal swab and deliver results in 20 minutes, is expected to help control the spread of Covid-19 in the country.

Quest Diagnostics has partnered with CLX Health, which operates the TrustAssure Testing Platform, to offer Covid-19 molecular diagnostic tests for individuals attending live events in the US or travelling internationally. People can use TrustAssure to schedule appointments for testing at certain Quest Diagnostics patient service centres and more than 750 retail partner pharmacy sites across the country. Test results will be delivered in 48 hours.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network